Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 5 Breast Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasms 3 Melanoma 3 Leukemia, Myeloid, Acute 3 Leukemia 3 Carcinoma, Non-Small-Cell Lung 3 Myelodysplastic Syndromes 2 Lymphoma, Mantle-Cell 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Hematologic Neoplasms 2 Craniopharyngioma 2 COVID-19 2 Burkitt Lymphoma 2 Arthritis, Rheumatoid 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Unresectable Pancreatic Carcinoma 1 Triple Negative Breast Neoplasms 1 Stroke 1 Sarcoma 1 Respiratory Tract Infections 1 Recurrence 1 Pulmonary Disease, Chronic Obstructive 1 Prostatic Neoplasms 1 Pleural Effusion, Malignant 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

tocilizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Unresectable Pancreatic Carcinoma × tocilizumab × Clear all

NCT02767557 2023-09-22

PACTO

Herlev Hospital

Phase 2 Completed

Gastrointestinal

Unresectable Pancreatic Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡